Fresenius Medical Care AG (BVMF:FMSC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 66.09B -13.4% |
| Revenue (ttm) | 114.99B -0.5% |
| Net Income | 5.55B +42.9% |
| EPS | 19.80 +50.0% |
| Shares Out | n/a |
| PE Ratio | 11.91 |
| Forward PE | 11.01 |
| Dividend | 3.03 (2.45%) |
| Ex-Dividend Date | May 21, 2026 |
| Volume | 4 |
| Open | 123.48 |
| Previous Close | n/a |
| Day's Range | 123.48 - 123.48 |
| 52-Week Range | 105.05 - 137.10 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial numbers in EUR Financial StatementsNews
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…
Fresenius Medical price target lowered to EUR 31 from EUR 32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 31 from EUR 32 and keeps an Underweight rating on the shares.
Fresenius Medical price target lowered to $25 from $26 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $25 from $26 and keeps a Hold rating on the shares.
Fresenius Medical Care AG Q2 Sales Increase
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius Medical Care AG (FME.DE) reported a profit for second quarter of EUR218 millionThe company's earnings totaled EUR218 million, or EUR0.81 per share. ...
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 5.0% -- What GF Score of 73 Tells Investors
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year out...
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Fresenius Medical Care AG Earnings Call Transcript: Q2 2026
Operating income grew 23% year-over-year with margin expansion and strong cash flow, despite U.S. treatment volume headwinds and regulatory challenges in China. A EUR 1 billion share buyback was completed and a second program launched, while guidance for 2026 was confirmed.
Fresenius Medical Care AG Earnings release: Q2 2026
Fresenius Medical Care AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Fresenius Medical Care AG Slides: Q2 2026
Fresenius Medical Care AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Fresenius Medical Care AG Quarterly report: Q2 2026
Fresenius Medical Care AG has published its Q2 2026 quarterly earnings report on August 4, 2026.
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's de...
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of market expectations and reaffirmed its full-year outlook, as its cost-cutting programme and favourable U.S. re...
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Results / Quarter Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectatio...
Fresenius Medical Care AG (FMS) Shares Surge 3.4% -- What GF Score of 76 Tells Investors
Fresenius Medical Care AG (FMS) Shares Surge 3.4% -- What GF Score of 76 Tells Investors
Fresenius Medical downgraded to Underperform from Neutral at BNP Paribas
BNP Paribas downgraded Fresenius Medical (FMS) to Underperform from Neutral with a $19.90 price target The firm expects U.S. dialysis volumes to “stay lower for longer.”
Fresenius Medical Care Launches TherapyWise Analytics For Kidney Care Programs
(RTTNews) - Fresenius Medical Care AG (FMS), a kidney care company, announced Monday the launch of TherapyWise, a cloud-based analytics within FDA 510(k) cleared NxView4.0 software for the NxStage Sys...
Fresenius Medical price target raised to EUR 41 from EUR 40 at Citi
Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 41 from EUR 40 and keeps a Neutral rating on the shares.
Fresenius Medical initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Fresenius Medical (FMS) with a Market Perform rating and EUR 44.65 price target Dialysis, particularly in the U.S. where the company is over-indexed, has been a…
Notable Two Hundred Day Moving Average Cross - FMS
In trading on Thursday, shares of Fresenius Medical Care (Symbol: FMS) crossed below their 200 day moving average of $23.63, changing hands as low as $23.05 per share. Fresenius Medical Care shares ar...
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. ...
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: ...